Contact
Mac MacDonaldLifeSci Advisors
mac@lifesciadvisors.com
Key Opinion Leader Lunch:
Treating Acute Vertigo
Hosted by Sensorion (Euronext Paris: ALSEN.PA)
RSVP Information
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only.
Please RSVP in advance if you plan to attend, as space is limited.
The meeting will feature a presentation by key opinion leader Steven D. Rauch, MD (Harvard Medical School), who will discuss the current treatment landscape, diagnosis and management of patients with balance disorders. Dr. Rauch will be available to answer questions following the lunch.
Sensorion's management team will also will provide an overview of the Company’s ongoing clinical development work with SENS-111, an oral novel small-molecule drug candidate, currently in Phase II for treating acute severe vertigo.
Steven D. Rauch, MD
Steven D. Rauch, MD is a Professor of Otolaryngology at Harvard Medical School, and Chief of the Vestibular Division at Massachusetts Eye and Ear. With more than 30 years of experience in otolaryngology, Dr. Steven Rauch specializes in otology, the diagnosis, medical, and surgical management of hearing and balance disorders. His clinical interests include both hearing and balance disorders. He focuses his research efforts on combined disorders of hearing and balance, particularly Ménière’s disease, autoimmune inner ear disease, sudden deafness, and migraine. Dr. Rauch has served as a member of the Board of Scientific Councilors of the NIH National Institute on Deafness and Other Communication Disorders (NIDCD) and as President of the Association for Research in Otolaryngology (ARO). He is also a Past Chair of the Research Advisory Board of the American Academy of Otolaryngology—Head and Neck Surgery. He is a member of the American Otological Society and the American Neurotological Society.